ProStrakan In Buyers' Sights After Setbacks
This article was originally published in The Pink Sheet Daily
Executive Summary
The specialty pharma company is 'evaluating interest' from buyers after delays to key drugs.
You may also be interested in...
ProStrakan Secures Offer From Japan's Kyowa Hakko, But Analysts Say Too Low
Three months after putting itself up for sale, U.K.-based specialty pharma firm ProStrakan Group PLC on Feb. 21 announced a cash offer from Japan's Kyowa Hakko Kirin Co. Ltd. The 130 pence-per-share deal values the company at about £292 million ($475 million)
ProStrakan Secures Offer From Japan's Kyowa Hakko, But Analysts Say Too Low
Kyowa Hakko Kirin's offer to buy U.K.-based specialty pharma ProStrakan values the company lower than other similar deals.
ProStrakan Secures Offer From Japan's Kyowa Hakko, But Analysts Say Too Low
Kyowa Hakko Kirin's offer to buy U.K.-based specialty pharma ProStrakan values the company lower than other similar deals.